近端食管癌根治性放化疗后的瑞士多中心回顾性结局
该研究回顾性分析了四家瑞士机构2004至2013年间接受铂类根治性放化疗的55例颈段食管癌患者,中位随访34个月,3年局部区域控制率、无病生存率和总生存率分别为52%、35%和52%,急性毒性为0至4级且无显著剂量依赖差异。
要点
- 3年局部区域控制率、无病生存率和总生存率分别为52%、35%和52%。
- 诊断至放化疗间隔超过78天是局部区域控制的唯一显著预后因素。
- 总剂量超过56Gy和诱导化疗与无病生存及总生存改善显著相关。
核心结论
- 根治性放化疗是近端食管癌可靠的治疗选择,治疗相关毒性可接受。
- 更高剂量和诱导化疗可能改善总生存和无病生存,但需前瞻性研究证实。
研究设计与样本
- 瑞士四家机构2004至2013年回顾性研究,纳入55例cT1-4 cN0-3 cM0颈段食管癌患者。
- 患者接受铂类根治性放化疗,急性与慢性毒性采用CTCAE-NCI v4.0回顾性评分。
- 主要终点为局部区域控制,次要终点包括总生存和无病生存,采用Log-rank检验和多因素Cox比例风险模型分析。
主要发现
- 中位随访34个月,3年局部区域控制率为52%(95% CI:37-67%)。
- 3年无病生存率为35%(95% CI:22-50%),3年总生存率为52%(95% CI:37-67%)。
- 急性毒性(吞咽困难、疼痛、皮肤毒性)为0至4级,无显著剂量依赖差异。
- 单因素分析中,诊断至放化疗间隔超过78天是局部区域控制的唯一显著预后因素。
- 多因素分析中,总放射剂量超过56Gy(p <0.006)和诱导化疗(p <0.004)是影响无病生存和总生存的显著阳性预测因素。
关键数值与推荐
- 中位放射剂量为56Gy(范围28-72Gy),58%的患者接受了诱导化疗。
- 诊断至放化疗的中位间隔为78天(范围6-178天)。
- 总剂量超过56Gy与无病生存和总生存改善显著相关(p <0.006)。
- 诱导化疗与无病生存和总生存改善显著相关(p <0.004)。
临床怎么用
- 对于近端食管癌,根治性放化疗是可行的治疗选择,毒性可接受。
- 考虑使用总剂量超过56Gy和诱导化疗以可能改善生存。
- 诊断至放化疗间隔超过78天与局部区域控制相关,应关注治疗及时性。
局限性
- 回顾性研究设计,样本量55例,结果需前瞻性研究证实。
- 急性与慢性毒性为回顾性评分,可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report oncological outcomes and toxicity rates, of definitive platin-based chemoradiadiationtherapy (CRT) in the management of proximal esophageal cancer. METHODS: We retrospectively reviewed the medical records of patients with cT1-4 cN0-3 cM0 cervical esophageal cancer (CEC) (defined as tumors located below the inferior border of the cricoid cartilage, down to 22 cm from the incisors) treated between 2004 and 2013 with platin-based definitive CRT in four Swiss institutions. Acute and chronic toxicities were retrospectively scored using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0 (CTCAE-NCI v.4.0). Primary endpoint was loco-regional control (LRC). We also evaluated overall survival (OS) and disease-free survival (DFS) rates. The influence of patient- and treatment related features have been calculated using the Log-rank test and multivariate Cox proportional hazards model. RESULTS: We enrolled a total of 55 patients. Median time interval from diagnosis to CRT was 78 days (6-178 days). Median radiation dose was 56Gy (28-72Gy). Induction chemotherapy (ICHT) was delivered in 58% of patients. With a median follow up of 34 months (6-110months), actuarial 3-year LRC, DFS and OS were 52% (95% CI: 37-67%), 35% (95% CI: 22-50%) and 52% (95% CI: 37-67%), respectively. Acute toxicities (dysphagia, pain, skin-toxicity) ranged from grade 0 - 4 without significant dose-dependent differences. On univariable analyses, the only significant prognostic factor for LRC was the time interval > 78 days from diagnosis to CRT. On multivariable analysis, total radiation dose >56Gy (p <0.006) and ICHT (p < 0.004) were statistically significant positive predictive factors influencing DFS and OS. CONCLUSION: Definitive CRT is a reliable therapeutic option for proximal esophageal cancer, with acceptable treatment related toxicities. Higher doses and ICHT may improve OS and DFS and. These findings need to be confirmed in further prospective studies.
引用
- Herrmann E, Mertineit N, De Bari B, et al. Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study. Radiat Oncol. 2017. PMID: 28615060. doi:10.1186/s13014-017-0834-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。